Plimoth Trust Co. LLC Has $1.51 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Plimoth Trust Co. LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 56,745 shares of the biopharmaceutical company’s stock after selling 4,765 shares during the period. Plimoth Trust Co. LLC’s holdings in Pfizer were worth $1,505,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. State Street Corp lifted its position in Pfizer by 1.2% during the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company’s stock valued at $8,405,930,000 after purchasing an additional 3,405,539 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares during the period. Geode Capital Management LLC lifted its position in Pfizer by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company’s stock valued at $3,392,342,000 after purchasing an additional 1,855,419 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Pfizer by 22.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the period. Finally, Swiss National Bank lifted its position in Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after purchasing an additional 100,900 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday. Guggenheim lowered their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Finally, Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

Shares of PFE traded up $0.18 during midday trading on Wednesday, reaching $26.93. 3,249,487 shares of the stock were exchanged, compared to its average volume of 34,193,898. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a market cap of $152.62 billion, a P/E ratio of 36.36, a PEG ratio of 0.64 and a beta of 0.64. The stock’s 50 day simple moving average is $26.18 and its 200 day simple moving average is $27.91.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business earned ($0.17) earnings per share. Pfizer’s revenue was up 31.2% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.39%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.